Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling.

Migliore C, Morando E, Ghiso E, Anastasi S, Leoni VP, Apicella M, Cora' D, Sapino A, Pietrantonio F, De Braud F, Columbano A, Segatto O, Giordano S.

EMBO Mol Med. 2018 Sep;10(9). pii: e8746. doi: 10.15252/emmm.201708746.

2.

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC.

Ghiso E, Migliore C, Ciciriello V, Morando E, Petrelli A, Corso S, De Luca E, Gatti G, Volante M, Giordano S.

Neoplasia. 2017 Dec;19(12):1012-1021. doi: 10.1016/j.neo.2017.10.003. Epub 2017 Nov 11.

3.

YAP activation is an early event and a potential therapeutic target in liver cancer development.

Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, Raschioni C, Testore E, Roncalli M, Giordano S, Columbano A.

J Hepatol. 2014 Nov;61(5):1088-96. doi: 10.1016/j.jhep.2014.06.033. Epub 2014 Jul 7.

4.

Targeting MET: why, where and how?

Ghiso E, Giordano S.

Curr Opin Pharmacol. 2013 Aug;13(4):511-8. doi: 10.1016/j.coph.2013.05.018. Epub 2013 Jun 21. Review.

PMID:
23797036
5.

Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression.

Petrelli A, Perra A, Schernhuber K, Cargnelutti M, Salvi A, Migliore C, Ghiso E, Benetti A, Barlati S, Ledda-Columbano GM, Portolani N, De Petro G, Columbano A, Giordano S.

Oncogene. 2012 Oct 18;31(42):4517-26. doi: 10.1038/onc.2011.631. Epub 2012 Jan 16.

6.

Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice.

Kowalik MA, Saliba C, Pibiri M, Perra A, Ledda-Columbano GM, Sarotto I, Ghiso E, Giordano S, Columbano A.

Hepatology. 2011 Jun;53(6):2086-96. doi: 10.1002/hep.24289. Epub 2011 May 13.

7.

Expression of c-jun is not mandatory for mouse hepatocyte proliferation induced by two nuclear receptor ligands: TCPOBOP and T3.

Leoni VP, Ledda-Columbano GM, Pibiri M, Saliba C, Perra A, Kowalik MA, Grober OM, Ravo M, Weisz A, Locker J, Ghiso E, Giordano S, Columbano A.

J Hepatol. 2011 Nov;55(5):1069-78. doi: 10.1016/j.jhep.2011.02.016. Epub 2011 Feb 25.

8.

MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.

Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T, Comoglio PM, Giordano S.

Cancer Res. 2010 Oct 1;70(19):7580-90. doi: 10.1158/0008-5472.CAN-10-0436. Epub 2010 Sep 14.

9.

Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.

Corso S, Ghiso E, Cepero V, Sierra JR, Migliore C, Bertotti A, Trusolino L, Comoglio PM, Giordano S.

Mol Cancer. 2010 May 26;9:121. doi: 10.1186/1476-4598-9-121.

10.

MicroRNAs impair MET-mediated invasive growth.

Migliore C, Petrelli A, Ghiso E, Corso S, Capparuccia L, Eramo A, Comoglio PM, Giordano S.

Cancer Res. 2008 Dec 15;68(24):10128-36. doi: 10.1158/0008-5472.CAN-08-2148.

11.

Silencing the MET oncogene leads to regression of experimental tumors and metastases.

Corso S, Migliore C, Ghiso E, De Rosa G, Comoglio PM, Giordano S.

Oncogene. 2008 Jan 24;27(5):684-93. Epub 2007 Aug 6.

PMID:
17684486

Supplemental Content

Support Center